Anti-reflux formula and metabolic acidosis in NICU infants: a retrospective cohort study
- 1Department of Pediatrics, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591 Republic of Korea
Abstract
Objective: To determine the incidence, time course, and reversibility of metabolic acidosis associated with anti-reflux (AR) formula in NICU infants, and to identify associated clinical factors.
Study design: Retrospective cohort study of 161 NICU infants receiving Novalac AR for ≥ 3 days with serial blood gas data (Level IV NICU, Seoul, 2021–2025).
Results: Pre-specified time-point analyses demonstrated significant acid–base deterioration at Day 3 (mean ΔBE − 2.14 mEq/L; p < 0.001; n = 110) and Day 7 (− 2.46 mEq/L; p < 0.001; n = 120). Nadir-based analysis showed mean base excess declining from 0.53 ± 3.02 to − 3.51 ± 3.18 mEq/L (mean ΔBE − 4.04 mEq/L; 95% CI − 4.54 to − 3.54; p < 0.001). New-onset metabolic acidosis occurred in 19/161 infants (11.8%) by primary definition (pH < 7.35, HCO₃⁻ <20 mmol/L, and BE < − 4 mEq/L) and 37/161 (23.0%) by broader definition (HCO₃⁻ <20 mmol/L and BE < − 4 mEq/L). Acid–base deterioration was detectable at a mean of 2.3 days after initiation and reached nadir at a median of 5.4 days (IQR 3.3–8.4); 37.3% of infants had their recorded nadir after day 7. Among 50 infants in whom AR formula was discontinued, base excess improved by a mean of + 2.78 mEq/L (p < 0.001), with 77.8% showing improvement from nadir. Both infants who underwent rechallenge following confirmed metabolic acidosis developed recurrent metabolic acidosis. Lower postmenstrual age (PMA) at initiation was the only independent predictor of acidosis risk on multivariable analysis (adjusted OR 0.71 per 1-week increase; 95% CI 0.57–0.89; p = 0.003).
Conclusion: AR formula use is temporally associated with acid–base changes consistent with a retrospective safety signal, meeting metabolic acidosis criteria in 11.8–23.0% of cases; these changes were reversible in most cases after discontinuation. Consideration of acid–base monitoring within the first week of initiation may be reasonable, pending prospective confirmation, with particular attention to infants at lower postmenstrual ages.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12887-026-07474-2.
Related
- Prognostic Value of Admission Serum Chloride and of the Composition of Metabolic Acidosis in Postoperative Intensive Care: A Single-Centre Retrospective Cohort Study
- A Synbiotic Infant Formula Promotes Balanced Immune-Microbiome Interactions in Term Infants: A Randomized Controlled Trial
- Disparities in Exclusive Human Milk Feeding and Unintended Formula Supplementation Among Infants Discharged Following Birth at an Academic Medical Center
- Sex and formula supplementation are correlates of fecal calprotectin in premature infants at 10-18 months corrected age.
- FeNO may serve as a noninvasive screening tool for gastroesophageal reflux disease in children under 5 years: a retrospective study.
BibTeX
@article{shin2026antireflux,
title = {{Anti-reflux formula and metabolic acidosis in NICU infants: a retrospective cohort study}},
author = {Jeongmin Shin and Min Soo Kim and Moon-Yeon Oh},
journal = {BMC Pediatrics},
year = {2026},
month = aug,
doi = {10.1186/s12887-026-07474-2},
url = {https://doi.org/10.1186/s12887-026-07474-2},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Anti-reflux formula and metabolic acidosis in NICU infants: a retrospective cohort study
AU - Jeongmin Shin
AU - Min Soo Kim
AU - Moon-Yeon Oh
PY - 2026
DA - 2026/08/01
JO - BMC Pediatrics
DO - 10.1186/s12887-026-07474-2
UR - https://doi.org/10.1186/s12887-026-07474-2
AB - Objective: To determine the incidence, time course, and reversibility of metabolic acidosis associated with anti-reflux (AR) formula in NICU infants, and to identify associated clinical factors. Study design: Retrospective cohort study of 161 NICU infants receiving Novalac AR for ≥ 3 days with serial blood gas data (Level IV NICU, Seoul, 2021–2025). Results: Pre-specified time-point analyses demonstrated significant acid–base deterioration at Day 3 (mean ΔBE − 2.14 mEq/L; p < 0.001; n = 110) and Day 7 (− 2.46 mEq/L; p < 0.001; n = 120). Nadir-based analysis showed mean base excess declining from 0.53 ± 3.02 to − 3.51 ± 3.18 mEq/L (mean ΔBE − 4.04 mEq/L; 95% CI − 4.54 to − 3.54; p < 0.001). New-onset metabolic acidosis occurred in 19/161 infants (11.8%) by primary definition (pH < 7.35, HCO₃⁻ <20 mmol/L, and BE < − 4 mEq/L) and 37/161 (23.0%) by broader definition (HCO₃⁻ <20 mmol/L and BE < − 4 mEq/L). Acid–base deterioration was detectable at a mean of 2.3 days after initiation and reached nadir at a median of 5.4 days (IQR 3.3–8.4); 37.3% of infants had their recorded nadir after day 7. Among 50 infants in whom AR formula was discontinued, base excess improved by a mean of + 2.78 mEq/L (p < 0.001), with 77.8% showing improvement from nadir. Both infants who underwent rechallenge following confirmed metabolic acidosis developed recurrent metabolic acidosis. Lower postmenstrual age (PMA) at initiation was the only independent predictor of acidosis risk on multivariable analysis (adjusted OR 0.71 per 1-week increase; 95% CI 0.57–0.89; p = 0.003). Conclusion: AR formula use is temporally associated with acid–base changes consistent with a retrospective safety signal, meeting metabolic acidosis criteria in 11.8–23.0% of cases; these changes were reversible in most cases after discontinuation. Consideration of acid–base monitoring within the first week of initiation may be reasonable, pending prospective confirmation, with particular attention to infants at lower postmenstrual ages. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12887-026-07474-2.
SN - 1471-2431
ER -